Literature DB >> 18519821

Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis.

Ingrid Melle1, Tor K Larsen, Ulrik Haahr, Svein Friis, Jan O Johannesen, Stein Opjordsmoen, Bjørn R Rund, Erik Simonsen, Per Vaglum, Thomas McGlashan.   

Abstract

BACKGROUND: The duration of untreated psychosis (DUP)-the time from onset of psychotic symptoms to the start of adequate treatment--is consistently correlated with better course and outcome, but the mechanisms are poorly understood.
OBJECTIVE: To report the effects of reducing DUP on 2-year course and outcome.
DESIGN: A total of 281 patients with a DSM-IV diagnosis of nonorganic, nonaffective psychosis coming to their first treatment during 4 consecutive years were recruited, of which 231 participated in the 2-year follow-up. A comprehensive early detection (ED) system, based on public information campaigns and low-threshold-psychosis-detecting teams, was introduced in 1 health care area (ED area), but not in a comparable area (no-ED area). Both areas ran equivalent 2-year treatment programs.
RESULTS: First-episode patients from the ED area had a significantly lower DUP, better clinical status, and milder negative symptoms at the start of treatment. There were no differences in treatment received for the first 2 years between the groups. The difference in negative symptoms was maintained at the 1-year follow-up. There was a statistically significant difference in the Positive and Negative Syndrome Scale negative component, cognitive component, and depressive component in favor of the ED group at the 2-year follow-up. Multiple linear regression analyses gave no indication that these differences were due to confounders.
CONCLUSION: Reducing the DUP has effects on the course of symptoms and functioning, including negative symptoms, suggesting secondary prevention of the negative psychopathologies in first-episode schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18519821     DOI: 10.1001/archpsyc.65.6.634

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  36 in total

Review 1.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

Review 2.  [Correlations between risk gene variants for schizophrenia and brain structure anomalies].

Authors:  T Nickl-Jockschat; M Rietschel; T Kircher
Journal:  Nervenarzt       Date:  2009-01       Impact factor: 1.214

Review 3.  Premorbid adjustment, onset types, and prognostic scaling: still informative?

Authors:  T H McGlashan
Journal:  Schizophr Bull       Date:  2008-06-26       Impact factor: 9.306

4.  Treatment timing vs treatment type in first-episode psychosis: a paradigm shift in strategy and effectiveness.

Authors:  Thomas H McGlashan
Journal:  Schizophr Bull       Date:  2012-09       Impact factor: 9.306

Review 5.  College Students: Mental Health Problems and Treatment Considerations.

Authors:  Paola Pedrelli; Maren Nyer; Albert Yeung; Courtney Zulauf; Timothy Wilens
Journal:  Acad Psychiatry       Date:  2014-08-21

6.  Improving outcomes of first-episode psychosis: an overview.

Authors:  Paolo Fusar-Poli; Patrick D McGorry; John M Kane
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

7.  Schizotypal personality questionnaire--brief revised (updated): An update of norms, factor structure, and item content in a large non-clinical young adult sample.

Authors:  Charlie A Davidson; Lesa Hoffman; William D Spaulding
Journal:  Psychiatry Res       Date:  2016-02-08       Impact factor: 3.222

8.  Characterization of the deficit syndrome in drug-naive schizophrenia patients: the role of spontaneous movement disorders and neurological soft signs.

Authors:  Victor Peralta; Lucía Moreno-Izco; Ana Sanchez-Torres; Elena García de Jalón; Maria S Campos; Manuel J Cuesta
Journal:  Schizophr Bull       Date:  2012-12-18       Impact factor: 9.306

9.  Advances in the genetics of schizophrenia: will high-risk copy number variants be useful in clinical genetics or diagnostics?

Authors:  David A Collier; Evangelos Vassos; Simon Holden; Christine Patch; Philip McGuire; Cathryn Lewis
Journal:  F1000 Med Rep       Date:  2009-08-17

10.  Apathy, poor verbal memory and male gender predict lower psychosocial functioning one year after the first treatment of psychosis.

Authors:  Ann Faerden; Elizabeth Ann Barrett; Ragnar Nesvåg; Svein Friis; Arnstein Finset; Stephen R Marder; Joseph Ventura; Ole A Andreassen; Ingrid Agartz; Ingrid Melle
Journal:  Psychiatry Res       Date:  2013-03-13       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.